- Home
- ALGS
as 05-14-2025 2:30pm EST
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 32.4M | IPO Year: | 2020 |
| Target Price: | $70.00 | AVG Volume (30 days): | 145.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -16.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.76 - $46.80 | Next Earning Date: | 05-06-2025 |
| Revenue: | $3,270,000 | Revenue Growth: | -76.29% |
| Revenue Growth (this year): | 583.52% | Revenue Growth (next year): | -94.96% |
Latest Aligos Therapeutics Inc. News
ALGS Breaking Stock News: Dive into ALGS Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Aligos Therapeutics First Quarter 2025 Earnings: Revenues Miss Expectations
GlobeNewswire
6 days ago
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
Zacks
8 days ago
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates
GlobeNewswire
8 days ago
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
The Fly
13 days ago
UPS downgraded, ServiceNow upgraded: Wall Street's top analyst calls
GlobeNewswire
15 days ago
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
GlobeNewswire
21 days ago
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
GlobeNewswire
2 months ago
Aligos Therapeutics Presents Positive Data at APASL 2025
Compare ALGS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALGS Aligos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.